Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies

A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Support for the approval comes from phase 3 LUNAR study findings indicating TTFields significantly prolonged OS compared with standard of care alone.